Literature DB >> 8877544

In-vitro interactions of DX-8739, a new carbapenem, meropenem and imipenem with amikacin against multiresistant Pseudomonas aeruginosa.

E J Giamarellos-Bourboulis1, P Grecka, H Giamarellou.   

Abstract

In order to investigate the antimicrobial interactions against multiresistant Pseudomonas aeruginosa, thirty-seven strains resistant to antimicrobial agents of five different chemical classes were exposed in vitro to the combination of three carbapenems. DX-8739, a novel DHP-I stable analogue, meropenem and imipenem with amikacin. The tested combinations expressed an enhanced killing activity against 38-46% of strains and an additive effect against 5-13%. These effects were the same whether the applied carbapenem was DX-8739, meropenem or imipenem; they were also independent of the MIC of any antimicrobial.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8877544     DOI: 10.1093/jac/38.2.287

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  3 in total

1.  In vitro activity of the aminoglycoside antibiotic arbekacin against Acinetobacter baumannii-calcoaceticus isolated from war-wounded patients at Walter Reed Army Medical Center.

Authors:  Michael J Zapor; Melissa Barber; Amy Summers; George H Miller; Lee Ann Feeney; Lynn E Eberly; Glenn Wortmann
Journal:  Antimicrob Agents Chemother       Date:  2010-04-19       Impact factor: 5.191

2.  In vitro antimicrobial effects of aztreonam, colistin, and the 3-drug combination of aztreonam, ceftazidime and amikacin on metallo-beta-lactamase-producing Pseudomonas aeruginosa.

Authors:  Shigeharu Oie; Yumi Fukui; Masaya Yamamoto; Yuki Masuda; Akira Kamiya
Journal:  BMC Infect Dis       Date:  2009-08-10       Impact factor: 3.090

3.  Serial granulocyte transfusions as a treatment for sepsis due to multidrug-resistant Pseudomonas aeruginosa in a neutropenic patient.

Authors:  Ying-Wei Lin; Souichi Adachi; Ken-Ichiro Watanabe; Katsutsugu Umeda; Tatsutoshi Nakahata
Journal:  J Clin Microbiol       Date:  2003-10       Impact factor: 5.948

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.